Skip to main content
Caplight Logo









B3 Therapeutics

Private
New Haven, ConnecticutHealthcare & Life Sciences

Last Round

Grant

Dec 5, 2024

Total Funding Raised

$30,000

Company Overview

B3 Therapeutics is a biotechnology company developing a novel approach to treat brain tumors using sustained-release, nanoparticle-encapsulated drugs delivered directly into the central nervous system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

nanoparticle drug deliverydrug delivery platformCNS drug deliveryblood-brain barrierbrain tumor treatmentnanomedicineneuro-oncologypolymer nanoparticlesCEDconvection-enhanced deliveryintrathecal deliveryglioblastomadiffuse intrinsic pontine gliomaDIPGbrain metastasesdrug encapsulationnucleic acid therapeuticsoligonucleotide deliverybiotech licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

B3 Therapeutics Comparables

Compare B3 Therapeutics with similar companies based on industry and business-model similarity.

B3 Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nanocarry Therapeutics
81%
B³ Pharma
81%
Gate2Brain
77%

B3 Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 5, 2024

B3 Therapeutics Investors

Notable investors and investment history

B3 Therapeutics investors
InvestorRounds
Blavatnik Fund for Innovation at YaleGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 5, 2024

    $30K grant from Blavatnik Fund for Innovation at Yale.

B3 Therapeutics Filings

Explore SEC and related filing metadata, where available.

B3 Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about B3 Therapeutics's valuation, stock price, and market status.

Is B3 Therapeutics a public or private company?

B3 Therapeutics is a private company.

What is the current stock price of B3 Therapeutics?

B3 Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is B3 Therapeutics worth (valuation)?

Valuation information for B3 Therapeutics is not publicly available.

Can I buy B3 Therapeutics stock?

B3 Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was B3 Therapeutics's last funding round?

B3 Therapeutics's most recent funding round was Grant on December 5, 2024.

Who are the main investors in B3 Therapeutics?

Key investors in B3 Therapeutics include Blavatnik Fund for Innovation at Yale.

Will B3 Therapeutics IPO soon?

No public IPO plans have been announced for B3 Therapeutics.

How can I track B3 Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor B3 Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew Haven, Connecticut
Year Founded2021
Last FundingDec 5, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?